Life Technologies Corp (LIFE): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Life Technologies ( LIFE) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.5%. By the end of trading, Life Technologies rose 53 cents (1.1%) to $46.93 on average volume. Throughout the day, two million shares of Life Technologies exchanged hands as compared to its average daily volume of 1.5 million shares. The stock ranged in a price between $46.13-$47.36 after having opened the day at $46.13 as compared to the previous trading day's close of $46.40. Other companies within the Health Care sector that increased today were: Galena Biopharma ( GALE), up 21.4%, OxiGene ( OXGN), up 20.9%, Catalyst Pharmaceutical Partners ( CPRX), up 17%, and Dynavax Technologies Corporation ( DVAX), up 13.4%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Life Technologies Corporation operates as a global life sciences company. Life Technologies has a market cap of $7.98 billion and is part of the health services industry. The company has a P/E ratio of 20.3, above the S&P 500 P/E ratio of 17.7. Shares are up 19.2% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Life Technologies a buy, no analysts rate it a sell, and seven rate it a hold.

TheStreet Ratings rates Life Technologies as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, solid stock price performance, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Cyclacel Pharmaceuticals ( CYCC), down 12.3%, iBio ( IBIO), down 10.7%, Nymox Pharmaceutical Corporation ( NYMX), down 10.4%, and Biostar Pharmaceuticals ( BSPM), down 10.2%, were all laggards within the health care sector with Humana ( HUM) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.